Press Releases >
Presentations & Publications
|
INTARCIA PRESS RELEASES
|
| Jun 28, 2010 |
Intarcia Therapeutics, Inc. Presents Positive ITCA 650 Phase 2 Study Results as a Late-Breaker at the American Diabetes Association 70th Scientific Sessions |
| Nov 06, 2009 |
Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting |
| Sept 30, 2009 |
Intarcia Therapeutics, Inc. Presents Positive Results of ITCA 650 Phase 1b Study in Type 2 Diabetes at the European Association for the Study of Diabetes Conference |
| Sept 17, 2009 |
Intarcia Therapeutics, Inc. Commences Enrollment of ITCA 650 Phase 2 Study in Type 2 Diabetes |
| June 8, 2009 |
Intarcia Therapeutics, Inc. Presents ITCA 650 Phase 1b Study Results as a Late-Breaker at the American Diabetes Association 69th Scientific Sessions |
May 27, 2009
|
Intarcia Therapeutics, Inc. Announces Acceptance of ITCA 650 Phase 1b Study for Late-breaker Presentation at the American Diabetes Association 69th Scientific Sessions |
| April 24, 2009 |
Intarcia Therapeutics, Inc. Completes Enrollment of Phase 1b Clinical Trial of ITCA 650 (DUROS delivery of exenatide) In Patients With Type 2 Diabetes |
| Sept 09, 2008 |
Intarcia Therapeutics, Inc. Announces Appointment of Kenneth Luskey, M.D. as Vice President, Clinical Research
|
| June 6, 2007 |
FierceBiotech Names Intarcia Therapeutics as
One of the “Fierce 15" Biotech Companies of 2007
|
| May 21, 2007 |
Intarcia Therapeutics Announces Presentation of Final Results from a Phase 2 Combination Study for the Treatment of Hepatitis C at the Digestive Disease Week Conference |
| April 12, 2007 |
Intarcia Therapeutics Announces Final Results From A Phase 2 Study Of Injectable Omega Interferon plus Ribavirin for the Treatment of Hepatitis C Genotype-1 |
| March 19, 2007 |
Intarcia Raises $50 Million in a Series BB Financing |
|
